Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries’ wholly owned subsidiary companies have received approval from the US Food and Drug Administration (USFDA) for YONSA (abiraterone acetate), a novel formulation in combination with methylprednisolone, for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

Earlier, the company had acquired YONSA from Churchill Pharmaceuticals and will commercialize YONSA in the US.

Sun Pharmaceutical Industries is the world’s fourth largest specialty generic pharmaceutical company and India’s top pharmaceutical company.